Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics

NCT02953639 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02953639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02953639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
December 12, 2019
Enrollment
214 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia